Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or
the "Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease and overall health,
announced today that the United Stated Patent and Trademark Office
(USPTO) has published notification of a Notice of Allowance for
Pivotal's U.S. Patent Application Serial Number 13/584,428 entitled
"Omega 3 Fatty Acid for use as a Prescription Medical Food and Omega
3 Fatty Acid Diagnostic Assay for the Dietary Management of
Cardiovascular patients with Cardiovascular Disease (CVD) who are
Deficient in Blood EPA and DHA Levels." This notice constitutes
allowance of the patent and impending issuance. The issued patent
would have a term that expires no earlier than in 2032.

The present invention provides a kit for the dietary management of
cardiovascular patients with cardiovascular disease who are deficient
in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)
levels. This kit includes a diagnostic assay for determining blood
levels of EPA, DHA and Docosapentaenoic acid (DPA) and a
pharmaceutical grade prescription medical food Omega-3 fatty acid
formulation containing about 90% or more Omega-3 fatty acids by
weight including a combination of EPA, DPA and DHA in a weight ratio
of EPA:DHA of 5.7:1 to 6.3:1. The sum of the EPA, DHA and DPA are
about 82% by weight of the total formulation and about 92% of the
total Omega-3 fatty acid content of the composition. EPA + DHA are
about 80% of the total formulation and about 89% of the total Omega-3
fatty acid content of the composition.

"This is a key patent in our portfolio that surrounds our unique
Omega-3 formulation," said Dr. George Jackowski, Pivotal's Founder
and Chief Scientific Officer. "In fact, in this allowed patent, we
were able to obtain separate independent claims to our unique Omega-3
formulation that is the basis of a series of products being
commercialized by Pivotal."

This application is part of Pivotal's expanding patent portfolio
that protects its unique formulation. The Company has a total of four
(4) issued and allowed patents and seven (7) patent applications
currently in prosecution in the U.S. The Company is pursuing patent
applications related to VASCAZEN(R)'s formulation, composition,
combinations with existing obesity and cardiovascular drugs and an
Omega-3 fatty acid diagnostic assay in the U.S. and in multiple
jurisdictions outside the United States.

About VASCAZEN(R)

VASCAZEN(R) is currently available in the U.S. as a
prescription-only medical food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular
patients. VASCAZEN(R) is a >90% pure Omega-3 with a proprietary 6:1
EPA:DHA fatty acid formulation, protected by a series of both U.S.
and foreign patents.

VASCAZEN(R) has been clinically shown to correct an Omega-3
deficiency within eight weeks of treatment with positive concomitant
effects on the lipid profiles, mainly a 48% reduction of
triglycerides and an increase of HDL without negative impact on the
LDL-C lipid profile.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO),
specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN(R) is a prescription only medical food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications. OMAZEN(R) is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN(R) is a patented product available
for sale and distribution in Canada. BeneFishial(TM) is the first
product in Pivotal's new nutraceutical product line, which has been
specifically designed to be sold in the OTC direct to retail or
direct to consumer markets.

Disclosure Notice

The information contained in this document is as April 1, 2015.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as of
the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

Company Contacts: Kristine DiMatteo, Communications and Public
Relations Manager, Phone: +1-905-856-9797 ext. 231, E-Mail:
kdimatteo@pivotaltherapeutics.us

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de